Clinical Trials Logo

Induction Chemotherapy clinical trials

View clinical trials related to Induction Chemotherapy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06093438 Recruiting - Cervical Cancer Clinical Trials

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Start date: July 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.

NCT ID: NCT05397769 Recruiting - Clinical trials for Induction Chemotherapy

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Start date: June 8, 2022
Phase: Phase 2
Study type: Interventional

Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy/30-33f, 5d/w,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.

NCT ID: NCT05114707 Recruiting - Clinical trials for Induction Chemotherapy

Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Start date: April 16, 2021
Phase: Phase 2
Study type: Interventional

Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for this study. All the eligible patients receive three cycles of induction chemotherapy (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides, camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the first day of induction chemotherapy. We aim to evaluate the three years failure free survival of these patients by the combination of camrelizumab with curative radiotherapy and chemotherapy.

NCT ID: NCT04539600 Recruiting - Immunotherapy Clinical Trials

Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer

Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

The study is a single center phase II trial. The purpose is to investigate both the efficacy and safety of chemotherapy combined with anti-PD-1 antibody Followed by chemoradiotherapy in locoregionally advanced hypopharyngeal cancer.

NCT ID: NCT04446130 Recruiting - Clinical trials for Induction Chemotherapy

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Start date: January 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.

NCT ID: NCT04087967 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of DAC combined with HAAG regimen in the induction treatment of newly diagnosed AML patients younger than 60 years.

NCT ID: NCT04083911 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60

Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of DAC combined with HAAG regimen in the induction treatment of newly diagnosed AML patients older than 60 years.

NCT ID: NCT02924909 Recruiting - Esophageal Cancer Clinical Trials

Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer

QUIMERA
Start date: February 1, 2017
Phase: Phase 2
Study type: Interventional

Phase II trial of induction chemotherapy with carboplatin AUC 6 plus paclitaxel 175 mg/m2 in a 21 day cycle for two cycles followed by radiotherapy 4500 cGy in 25 fractions plus carboplatin AUC=2 paclitaxel 50 mg/m2 in a week regimen followed by minimally invasive surgery after 6 to 10 weeks. A PET scan will be performed at the time of randomization and 14 days after de first cycle to determine the relation between metabolic response and survival.